Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Assessment of the Gastrointestinal System I: Subjective Data01:17

Assessment of the Gastrointestinal System I: Subjective Data

390
Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
390
Gastrointestinal Motility Disorders01:20

Gastrointestinal Motility Disorders

735
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
735
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.0K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.0K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

599
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
599
Assessment of the Gastrointestinal System II: Health Perception Pattern01:29

Assessment of the Gastrointestinal System II: Health Perception Pattern

241
Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health Perception Patterns
Health perception patterns offer valuable insights into a patient's lifestyle habits and how they may impact their GI health. These patterns include:
241
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

801
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
801

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Constipation Is Linked to Neuroinflammation in Early Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2025
Same author

rs6971 TSPO polymorphism in Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society·2025
Same author

"Recommendations for clinical study protocols for immune and inflammatory profiling in Parkinson's disease".

NPJ Parkinson's disease·2025
Same author

Pharmacological and pupillary evidence for the noradrenergic contribution to reinforcement learning in Parkinson's disease.

Communications biology·2025
Same author

Beta-adrenoceptor drugs and progression to Parkinson's disease milestones in a large pooled incident cohort.

NPJ Parkinson's disease·2025
Same author

Genetic Analysis of the X Chromosome Associates Loci with Progression of Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2025

Related Experiment Video

Updated: Nov 2, 2025

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease
03:20

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease

Published on: September 22, 2023

2.1K

The Gastrointestinal Dysfunction Scale for Parkinson's Disease.

Marta Camacho1, Julia C Greenland1, Caroline H Williams-Gray1

  • 1John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.

Movement Disorders : Official Journal of the Movement Disorder Society
|June 16, 2021
PubMed
Summary

A new scale quantifies gastrointestinal symptoms in Parkinson's disease (PD). The Gastrointestinal Dysfunction Scale for Parkinson's Disease shows strong reliability and validity for assessing PD-related gut issues.

Keywords:
GIDS-PDParkinson's diseasegastrointestinalpatient-report outcome measurescale

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.1K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

15.5K

Related Experiment Videos

Last Updated: Nov 2, 2025

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease
03:20

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease

Published on: September 22, 2023

2.1K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.1K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

15.5K

Area of Science:

  • Neurology
  • Gastroenterology
  • Psychometrics

Background:

  • Gastrointestinal dysfunction is a significant feature of Parkinson's disease (PD).
  • Current assessment methods for gastrointestinal dysfunction in PD lack standardization.
  • There is a need for a specific, quantitative tool to evaluate gastrointestinal symptoms in PD patients.

Purpose of the Study:

  • To develop and validate the Gastrointestinal Dysfunction Scale for Parkinson's Disease (GIDS-PD).
  • To create a self-report instrument for quantitative assessment of gastrointestinal symptoms in PD.

Main Methods:

  • Literature review and focus groups informed the development of the GIDS-PD.
  • 316 PD patients and 55 controls completed the GIDS-PD and other validated scales.
  • Psychometric properties including reliability and validity were evaluated.

Main Results:

  • The GIDS-PD demonstrated good internal consistency (Cronbach's α = 0.82) and test-retest stability.
  • Correlation analyses supported convergent and divergent validity.
  • A cutoff score on the constipation subscale effectively discriminated between PD patients with and without constipation.

Conclusions:

  • The GIDS-PD is a reliable and valid self-report tool for assessing gastrointestinal dysfunction in Parkinson's disease.
  • This novel scale allows for quantitative evaluation of gastrointestinal symptoms specific to PD.
  • Further longitudinal studies are recommended to track gastrointestinal dysfunction in PD cohorts.